Stock BLPH BELLEROPHON THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Bellerophon Therapeutics, Inc.

Equities

BLPH

US0787713009

Delayed OTC Markets
Other stock markets
 14:30:00 10/05/2024 BST 		5-day change 1st Jan Change
0.0562 USD 0.00% Intraday chart for Bellerophon Therapeutics, Inc. +0.36% +51.89%
05-02 North American Morning Briefing : Stock Futures -2- DJ
04-25 North American Morning Briefing : More Tech -2- DJ

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Bellerophon Therapeutics, Inc. Announces Resignation of Mary Ann Cloyd and Scott Bruder as Members of Board of Directors
Bellerophon Therapeutics, Inc. Announces Executive Changes
Bellerophon Therapeutics, Inc. Announces Executive Changes
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Bellerophon Therapeutics Insider Sold Shares Worth $111,776, According to a Recent SEC Filing
Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Investors Parse Inflation Data as Wall Street Set to Open Higher in Friday Trading
Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director
Bellerophon Therapeutics Announces Separation of Peter Fernandes as Chief Executive Officer, Effective July 15, 2023
Top Midday Decliners
Bellerophon's Phase 3 Study of INOpulse for Lung Disease Fails to Meet Primary Endpoint; Shares Plunge
Bellerophon Therapeutics, Inc. Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
Sector Update: Health Care Stocks Rising Late Friday
Sector Update: Health Care Stocks Rising Friday Afternoon
Bellerophon Therapeutics Files $150 Million Mixed Shelf
Bellerophon Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Bellerophon Therapeutics, Inc. Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease
Bellerophon Therapeutics, Inc. Announces Resignation of Nicholas Laccona as Principal Financial and Accounting Officer
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BLPH Stock
  4. News Bellerophon Therapeutics, Inc.
  5. Other languages